维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="OUARET"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Improved side information generation for distributed video coding by exploiting spatial and temporal correlations显示文摘	YE Shuiming OUARET M DUFAUX F		0，，01：	1
2	Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D El Ouadrani K		0，，01：	1
3	Targeting EGFR and VEGF (R)pathway cross -talk in tumor survival and angiogenesis 显示文摘	Larsen AK Ouaret D E10uadrani K	2011	Pharmacol Ther2011，131，1：	1
4	Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis 显示文摘	Larsen AK Ouaret D E10uadrani K	2011	Pharmacol Ther2011，131，1：	1
5	Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK1 Ouaret D El Ouadrani K	2011	Pharmacol Ther2011，131，1：	1
6	Targeting EGFR and VEGF(R)pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D El Ouadrani K	2011	Pharmacol Ther2011，131，1：	1
7	Targeting EGFR and VEGF(R)pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D El Ouadrani K		0，，01：	1
8	Targeting EG- FR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D E10uadrani K	2011	Pharmacol Ther2011，131，1：	1
9	EGFR-andVEGF(R)-targeted small molecules show synergisticactivity in colorectal cancer models refractory to combinationsof monoclonal antibodies显示文摘	Poindessous V Ouaret D Battistella A	2011	Clin Cancer Res2011，17，20：	1
10	Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D El Ouadrani K		0，，：	1
11	Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis 显示文摘	Larsen AK Ouaret D E10uadrani K	2011	Pharmacol Ther2011，131，1：	1
12	Targeting EGFR and vegf(r) pathway cross-talk in tumor survival and angiogenesis显示文摘	LARSEN A K OUARET D EI-OUADRANI K	2011	Pharmacol Ther2011，131，1：	1
13	Protein kinase C 13 inhibition by enzastaurin leads to mitotic misscgregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN)显示文摘	Ouaret D Larsen AK	2014	Cell Cycle2014，13，17：	1
14	EGFR- and VEGF (R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combina- tions of monoelonal antibodies 显示文摘	Poindessous V Ouaret D E1 Ouadrani K	2011	Clin Cancer Res2011，17，20：	1
15	Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis显示文摘	Larsen AK Ouaret D ElOuadrani K		0，，01：	1
16	Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer显示文摘Objective: Patients with BRAF-mutant colorectal cancer(CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with known BRAF status.Methods: We screened 298 oncological drugs with and without ionising radiation in colorectal cancer cells isogenic for BRAF. Hits from rank product analysis were validated in a 16-cell line panel of human CRC cell lines, using clonogenic survival assays and xenograft models in vivo.Results: Most consistently identified hits were drugs targeting cell growth/proliferation or DNA damage repair. The most effective class of drugs that radiosensitised wild-type and mutant cell lines was PARP inhibitors. In clonogenic survival assays, talazoparib produced a radiation enhancement ratio of 1.9 in DLD1(BRAF-wildtype) cells and 1.8 in RKO(BRAF V600 E) cells. In DLD1 xenografts, talazoparib significantly increased the inhibitory effect of radiation on tumour growth(P ≤ 0.01).Conclusions: Our method for screening large drug libraries for radiosensitisation has identified PARP inhibitors as promising radiosensitisers of colorectal cancer cells with wild-type and mutant BRAF backgrounds.	Rebecca Carter Azadeh Cheraghchi-Bashi Adam Westhorpe Sheng Yu Yasmin Shanneik Elena Seraia Djamila Ouaret Yasuhiro Inoue Catherine Koch Jenny Wilding Daniel Ebner Anderson J. Ryan Francesca M. Buffa Ricky A. Sharma	2019	Cancer Biology & Medicine2019，16，2：	1
17	EGFR- and VEGF (R)-targeted small molecules show synergistic ac- tivity in colorectal cancer models refractory to combina- tions of monoclonal antibodies 显示文摘	Poindessous V Ouaret D E1 OK	2011	Clin Cancer Res2011，17，20：	1
18	Polytechnique Federale de Lau- sanne , Improved Side Information Generation with Iterative Deco- ding and Frame Interpolation for Distributed Video Coding IEEE 显示文摘	Ye S Ouaret M Dufaux F	2008	2008，，：	1
19	Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalised therapeutic assays 显示文摘	ASHLEY N JONES M OUARET D	2014	J Pathol2014，1，1：	1
20	Protein kinase C beta inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN) 显示文摘	Ouaret D Larsen AK	2014	Cell Cycle2014，13，17：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示